PAIN CONTROL > INJECTABLE ANESTHETICS Back to products list

Lignospan® standard

Lidocaine HCl. 2% and Epinephrine 1:100,000 Injection, USP

Indications

  • Local dental anesthesia by nerve block or infiltration.

Features & Benefits

  • Lignospan when used for infiltration will have an average onset time of less than two minutes and a duration of about 60 minutes. When used for nerve blocks the average onset time is 2 to 4 minutes and will provide about 90 minutes of pulpal anesthesia.
  • No-methylparaben formulation to avoid allergic reactions on sensitive patients.
  • 100 percent latex free components to help reduce allergic responses.
  • Terminal sterilization of product/cartridges for safe use.
  • Mylar label covered glass cartridges to minimize risk of wound in the event of a cartridge breakage.
  • Cartridges packed 10 to a blister tray to avoid glass to glass contact, hence reducing breakage.

Presentation

  • Item#01A1100 - Box containing 5 blisters of 10 x 1.7 ml glass cartridges.

Risk Information

Reactions to Lignspan® are characteristic of those associated with other amide-type local anesthetics. A major cause of adverse reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, inadvertent intravascular injection or slow metabolic degradation. Lignospan® is contraindicated in patients with a known hypersensitivity to it or to any local anesthetic agent of the amide type or to other components of lidocaine solutions. Local anesthetics should be employed only by clinicians who are well versed in diagnosis and management of dose-related toxicity and other acute emergencies which might arise from the block to be employed, and then only after insuring the immediate availability of oxygen, other resuscitative drugs, cardiopulmonary resuscitative equipment, and the personnel resources needed for proper management of toxic reactions and related emergencies. Lignospan® contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Please see package insert for prescribing information.